

The impact of REStrictive versUs

Liberal Transfusion

strategy on cardiac injury and
death in patients undergoing
surgery for Hip Fracture

NEWSLETTER

19th December 2022 Issue 3

Recruitment

- The current number of participants recruited to 19th December stands at 56 – well done all!
- Recruitment began on 10th June 2022 and we now have 12 sites open to recruitment, and 2 sites pending SIVs -A very warm welcome to all!
- We are nearing the end of our pilot phase of the study (31st Jan 2023). The NIHR stop-go criteria are shown on the next page. If your site is a large site, we are asking for 1 randomization a week and for smaller sites, every fortnight. Sites hitting the milestone figures (60th, 75th, etc.) will receive tokens of our appreciation. Thank you in advance for your efforts!

Site Map



Recruitment per site per month

Site	Open	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Total
Edinburgh	10-Jun-22	2	5	1	3	5	4	3	23
Rotherham	20-Jun-22	1	0	1	1	0	0	1	4
Durham	30-Jun-22	-	3	2	2	2	2	1	12
Lanarkshire	05-Sep-22	-	-	-	1	5	2		8
Glasgow	21-Sep-22	-	-	-	-	0	0	1	1
Oxford	29-Sep-22	-	-	-	-	2	2		4
Borders	31-Oct-22	-	-	-	-	-	0		0
Newcastle	31-Oct-22	-	-	-	-	-	1	3	4
Total		3	8	4	7	14	11	9	56

THANK YOU FOR YOUR CONTINUED SUPPORT!

Green – Open
Orange – SIV completed
Blue – SIV pending









The impact of REStrictive versUs Liberal Transfusion strategy on cardiac injury and death in patients undergoing surgery for Hip Fracture

NEWSLETTER

19th December 2022 Issue 3

<u>FAQs -</u> Screening FAQs. This issue will focus on issues sites have raised around the screening process:

A patient / Next of Kin has declined participation in the study, how do I document this on the screening log?

Please use Exclusion Criteria 2 "unable to consent" if the below apply:

- a) patient or NoK has declined
- b) unable to reach NoK if have tried to consent
- c) tried to consent, but patient be discharged / transferred prior to consent

If have not attempted to consent the patient, please document in the reason why in reason why patient not pre-consented column with the most appropriate response.

A patient we are screening has had a blood transfusion clinically, are they still eligible to be included?

Yes, if the Hb falls again while in the screening period the patient would still be eligible to participate despite having a blood transfusion clinically.

A patient's Hb has reached the randomisation trigger (Hb <90) but they are not pre-consented to the trial, can I still approach for consent?

Yes, please approach for consent. If obtained randomise if Hb remains 90 or below.

During the screening process patient has become covid positive, are we still able to enrol?

Yes, if acceptable with local policy in regards to sample processing. If enrolled and samples obtained please note on the sample logs which samples are from covid positive patients.

*NIHR Red/Amber/Green trial progression criteria

Sites Open/Recruiting

<5 red; 5 -10 amber; >10 green

Participants randomised

<75 red; 75 -130 amber; >130 green)

Protocol adherence

<70% red; 70-90% amber; >90% green)

Recruitment rate/site/month open

<2.2 red; 2.2 – 3.7 amber; >3.7 green



Reminders

- Please enter your screening logs on to the database weekly.
- Data queries will be sent out to sites at the start of every month – please complete these as promptly as you can.
- If you have any **photos** that we can use in future newsletters, please do send them to us!
- We are registered for the NIHR Associate PI Scheme –
 if your site is interested in having an API, please contact
 us and we can advise on how to proceed.

Contact Information

Study Mailbox: RESULTHip.trial@ed.ac.uk

Chief Investigator:

Prof. Michael Gillies Michael.Gillies@ed.ac.uk

Lead Research Nurse/Clinical Coordinator:

Sophie Birch, 0131 242 3164

Sophie.Birch@nhslothian.scot.nhs.uk

Trial Manager:

Gayle Beveridge, 0131 651 9906 gayle.beveridge@ed.ac.uk

Assistant Trial Manager:

Stephanie O'Donovan, 0131 651 9937 Stephanie.O'Donovan@ed.ac.uk

Trial Website: https://edin.ac/result-hip
Trial Twitter: https://twitter.com/HipTrial